Wright Medical gets a date with the FDA and a chance to have the agency withdraw its “not approvable” letter for Wright’s Augment bone graft; net losses soar in Q3 on accounting write offs. Wright Medical (NSDQ:WMGI) officials said the FDA has agreed to hold a dispute resolution panel for the orthopedic company’s Augment Bone Graft product, which was denied approval by the agency in August. The news, as well as results from the company’s 3rd quarter, preceded a 4% jump in WMGI shares, which closed at $27.62 Tuesday night.
Help employers find you! Check out all the jobs and post your resume.
